Sign in
WithdrawnNo phase

HIV-1 and Brain Interaction on Smoking Comorbidity

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Withdrawn
Started
1 Dec 2019
Ended
30 Oct 2025
Type of study
Interventional, 8 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tobacco smoking and nicotine patch
Record updated
10 March 2020
Why it stopped
We originally had a collaboration with a PI but he has left the University.

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Subjects between ages 18-60 in good health
  • Ability to give written informed consent
  • For people living with HIV: should be diagnosed with HIV two years or more and on ART two years or more
  • For people living with HIV: should have achieved virologic suppression (defined as viral loads of ≤ 200 copies/ml), and without current signs of reactivation

Who cannot take part

  • Significant alcohol or other drug use, other than nicotine dependence or marijuana use
  • Unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or claustrophobic to the scanner
  • Any major medical illnesses to include, but not limited to, uncontrolled high blood pressure or high blood sugar, cardiovascular disease, asthma, peripheral vascular diseases, coagulopathies, history of superficial or deep vein thrombosis as per medical history
  • Current substance-induced psychiatric disorders
  • Gross structural abnormalities and/or have a history of syncope
  • Any neurological illnesses to include, but not limited to, seizure disorders, multiple sclerosis, movement disorders, or history of head trauma, CVA, CNS tumor,
  • For people living with HIV: having AIDS or non-AIDS-defining cancer or active CNS and other opportunistic disease
  • For people living with HIV: on active treatment of hepatitis C virus (HCV)
  • Inability to sign informed consent
  • Positive urine pregnancy tests

Where in United States

  • University of Maryland School of MedicineBaltimore, United States

About the trial

What the trial wants to find out

People living with HIV-1 have high rates of cigarette smoking, which may be related to nicotinic interaction with HIV-1 infection and brain function levels. The proposed project aims to understand these pathways using translational brain imaging and HIV-1 reactivation studies. The study proposes a targeted nicotine-brain investigation of the nicotinic effects in HIV-1 infection from cellular to brain circuitry levels.

The 8 groups in the trial

  • HIV-1 smokersTreatment being tested

    Treatment: Tobacco smoking and nicotine patch

  • HIV-1 nonsmokersNo study treatment, for comparison
  • Healthy control smokersExisting treatment, for comparison

    Treatment: Tobacco smoking and nicotine patch

  • Healthy control nonsmokersNo study treatment, for comparison
  • HIV-1 nonsmokers using nicotine patchExisting treatment, for comparison

    Treatment: Tobacco smoking and nicotine patch

  • HIV-1 nonsmokers using placebo patchNo study treatment, for comparison
  • Healthy control nonsmokers using nicotine patchExisting treatment, for comparison

    Treatment: Tobacco smoking and nicotine patch

  • Healthy control nonsmokers using placebo patchNo study treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
10 March 2020